radiolabeled bombesin derivatives (Bayer Schering)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameradiolabeled bombesin derivatives (Bayer Schering)
Drug Alias Name177Lu-P2349P-2349-[177Lu]RM-2-[177Lu]177Lu-RM-2Lu-177-labeled bombesin derivatives (Bayer Schering) +[8
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionBombesin receptor antagonists
TargetsBombesin receptor
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBayer Schering Pharma AG
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBayer Schering Pharma AG
Active IndicationsN/A
Inactive IndicationsProstatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A